La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Relmada Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Relmada Therapeutics..

Relmada Therapeutics (NASDAQ:RLMD) Azioni, Catena delle Opzioni

Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics Inc

News

Management

Press Releases

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Earnings

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Health Care

Relmada Issues Mid-Year CEO Letter to Shareholders

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Events

Sidoti Events, LLC's Virtual September Small-Cap Conference

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

ASTE

CMCO

CRAI

CSE:BOIL

DAKT

DYAI

FBRT

FFAI

FMAO

FSTR

GAIA

GAMI

GLDD

HIPO

HITI

HURN

HWKN

IDCC

IIIN

KELYA

KFRC

KGEI

KINS

LICT

LXFR

MAGN

MATV

MPTI

MTUS

NMTC

ONIT

OPRT

OSPN

PKOH

PLCE

PLUS

PSTL

RELL

RLMD

ROCK

SLVM

STRR

UXIN

VNCE

VREX

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Assertio Holdings

Biote

Context Therapeutics

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics

Grace Therapeutics

Hyperion DeFi

ImageneBio

Intercure

Incannex Healthcare

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

NRX Pharmaceuticals

Nasus Pharma

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Talphera

Turn Therapeutics

Tvardi Therapeutics

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Mizuho

Leerink Partners

Jefferies

Goldman Sachs

RELMADA THERAPEUTICS by Relmada Therapeutics, Inc.

Comments

Relmada Therapeutics

Relmada Therapeutics (RLMD) Opzioni

Relmada Therapeutics (NASDAQ:RLMD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO